[1] |
ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun.
Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021
[J]. China Oncology, 2022, 32(1): 1-12.
|
[2] |
JIA Zhenzhen, HE Shuang, LI Yangyang, WEN Feifei, XU Xiaoyang, GUO Ningjie, WU Shuhua.
Correlations between expressions of DPD, LC3 and P62 in colorectal cancer and their clinical significance
[J]. China Oncology, 2022, 32(1): 24-33.
|
[3] |
ZHANG Chi, CHEN Jiahui, LIN Jinyi, WANG Yan, ZHANG Sijia, ZHU Wei, CHENG Leilei.
Validation of a scale for evaluating the cardiovascular risk after breast cancer therapy: the clinical scale for breast cancer treatment related cardiovascular toxicity
[J]. China Oncology, 2022, 32(1): 54-60.
|
[4] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Targeting DNA damage response deficiency in the treatment of breast cancer
[J]. China Oncology, 2022, 32(1): 61-67.
|
[5] |
XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
A systematic review of current advancements of artificial intelligence in genitourinary cancers
[J]. China Oncology, 2022, 32(1): 68-74.
|
[6] |
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) .
Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition)
[J]. China Oncology, 2022, 32(1): 80-89.
|
[7] |
WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying .
Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration
[J]. China Oncology, 2021, 31(9): 775-782.
|
[8] |
ZHANG Xiaoyan , LI Qingxiang , LIU Yong , LI Hang , QIU Lijuan , FENG Xinran , TAN Liming .
A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer
[J]. China Oncology, 2021, 31(9): 783-788.
|
[9] |
CAO Ailing, CAO Zhe, ZHOU Jian.
Effects of docetaxel combined with thymosin α1 on number of Treg in immune microenvironment of rats with breast cancer and its mechanism
[J]. China Oncology, 2021, 31(9): 799-806.
|
[10] |
YAO Jia , LI Guanqiao , YANG Shiping , SU Huiluan .
Effect of hsa-miR-98-5p/DKK3 signal axis on biological behavior of breast cancer cells
[J]. China Oncology, 2021, 31(9): 807-816.
|
[11] |
LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin.
The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer
[J]. China Oncology, 2021, 31(9): 838-844.
|
[12] |
MA Yifei , LIANG Xinjun , WEI Shaozhong .
Prognostic value of inflammatory and immune markers in resectable colorectal cancer
[J]. China Oncology, 2021, 31(9): 845-851.
|
[13] |
Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association.
Clinical practice guidelines for cancer-related fatigue in China (2021 edition)
[J]. China Oncology, 2021, 31(9): 852-872.
|
[14] |
CONG Binbin, WANG Yongsheng.
Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer
[J]. China Oncology, 2021, 31(8): 689-696.
|
[15] |
FANG Yanhui , MA Caijuan , ZHANG Chunli , ZHAI Jiawei , ZHU Qiaoying , LIU Yin , ZHAO Xiwa .
miR-496 inhibits proliferation, migration and invasion of HeLa cell in cervical cancer via SFMBT1
[J]. China Oncology, 2021, 31(8): 697-703.
|